{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:55Z","timestamp":1790724535446,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["M4\/7"],"award-info":[{"award-number":["M4\/7"]}]},{"name":"Sbarro Health Research Organization (www.shro.org)","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"the Commonwealth of Pennsylvania","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AIL (Italian Association against Leukemia-Lymphoma and Myeloma Division \u201cValentina Picazio\u201d)","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Malignant mesothelioma (MM) is an aggressive asbestos-related cancer, against which no curative modalities exist. Oncolytic virotherapy is a promising therapeutic approach, for which MM is an ideal candidate; indeed, the pleural location provides direct access for the intra-tumoral injection of oncolytic viruses (OVs). Some non-human OVs offer advantages over human OVs, including the non-pathogenicity in humans and the absence of pre-existing immunity. We previously showed that caprine herpesvirus 1 (CpHV-1), a non-pathogenic virus for humans, can kill different human cancer cell lines. Here, we assessed CpHV-1 effects on MM (NCI-H28, MSTO, NCI-H2052) and non-tumor mesothelial (MET-5A) cells. We found that CpHV-1 reduced cell viability and clonogenic potential in all MM cell lines without affecting non-tumor cells, in which, indeed, we did not detect intracellular viral DNA after treatment. In particular, CpHV-1 induced MM cell apoptosis and accumulation in G0\/G1 or S cell cycle phases. Moreover, CpHV-1 strongly synergized with cisplatin, the drug currently used in MM chemotherapy, and this agent combination did not affect normal mesothelial cells. Although further studies are required to elucidate the mechanisms underlying the selective CpHV-1 action on MM cells, our data suggest that the CpHV-1-cisplatin combination could be a feasible strategy against MM.<\/jats:p>","DOI":"10.3390\/v13122458","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T23:30:00Z","timestamp":1639006200000},"page":"2458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-5844","authenticated-orcid":false,"given":"Iris Maria","family":"Forte","sequence":"first","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Indovina","sequence":"additional","affiliation":[{"name":"Institute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), 80131 Naples, Italy"},{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-8774","authenticated-orcid":false,"given":"Serena","family":"Montagnaro","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine and Animal Productions, University of Naples \u201cFederico II\u201d, 80137 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelina Antonella","family":"Iannuzzi","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Capone","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Unit\u2014Laboratories of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura deiTumori \u201cFondazione G. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-9740","authenticated-orcid":false,"given":"Rosa","family":"Camerlingo","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-2835","authenticated-orcid":false,"given":"Anna Maria","family":"Malfitano","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze Mediche Traslazionali, Universit\u00e0 di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-6801","authenticated-orcid":false,"given":"Francesca","family":"Pentimalli","sequence":"additional","affiliation":[{"name":"Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine and Animal Productions, University of Naples \u201cFederico II\u201d, 80137 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliamo","family":"Quintiliani","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-9769","authenticated-orcid":false,"given":"Giuseppe","family":"Portella","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze Mediche Traslazionali, Universit\u00e0 di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-016X","authenticated-orcid":false,"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA"},{"name":"Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ciarcia","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine and Animal Productions, University of Naples \u201cFederico II\u201d, 80137 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification","volume":"11","author":"Salle","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: Recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Oehl, K., Vrugt, B., Opitz, I., and Meerang, M. (2018). Heterogeneity in Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061603"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcancer.2019.09.014","article-title":"Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies","volume":"61","author":"Hinz","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Indovina, P., Forte, I.M., Pentimalli, F., and Giordano, A. (2020). Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade. Cancers, 12.","DOI":"10.3390\/cancers12071866"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jare.2014.11.012","article-title":"Mesothelioma treatment: Are we on target? A review","volume":"6","author":"Hiddinga","year":"2014","journal-title":"J. Adv. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future","volume":"9","author":"Nicolini","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1470-2045(17)30459-X","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): Final results from a single-centre, phase 2 trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","article-title":"Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives","volume":"8","author":"Guo","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102617","DOI":"10.18632\/oncotarget.18309","article-title":"Review: Oncolytic virotherapy, updates and future directions","volume":"8","author":"Fountzilas","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113986","DOI":"10.1016\/j.bcp.2020.113986","article-title":"Virotherapy: From single agents to combinatorial treatments","volume":"177","author":"Malfitano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1581528","DOI":"10.1080\/2162402X.2019.1596006","article-title":"Oncolytic viruses: How \u201clytic\u201d must they be for therapeutic efficacy?","volume":"8","author":"Davola","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic Viral Therapy for Mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fonc.2019.00564","article-title":"The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth","volume":"9","author":"Iannuzzi","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Iannuzzi, C., Indovina, P., Forte, I., Di Somma, S., Malfitano, A., Bruno, M., Portella, G., Pentimalli, F., and Giordano, A. (2020). Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197333"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/sj.cgt.7700946","article-title":"Herpes simplex virus 1 (HSV-1) for cancer treatment","volume":"13","author":"Shen","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Menotti, L., and Avitabile, E. (2020). Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218310"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/1535370219861928","article-title":"The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice","volume":"244","author":"Cai","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1080\/10717544.2018.1534895","article-title":"Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins","volume":"25","author":"Liu","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.2173860","article-title":"Mapping of Herpes Simplex Virus-1 Neurovirulence to \u03b3 134.5, a Gene Nonessential for Growth in Culture","volume":"250","author":"Chou","year":"1990","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-0774.2002.tb00109.x","article-title":"Oncolytic Virus Therapy Using Genetically Engineered Herpes Simplex Viruses","volume":"15","author":"Todo","year":"2002","journal-title":"Hum. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/cgt.2009.77","article-title":"Bovine herpesvirus type 1 as a novel oncolytic virus","volume":"17","author":"Rodrigues","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Burman, B., Pesci, G., and Zamarin, D. (2020). Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12123552"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bretscher, C., and Marchini, A. (2019). H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Viruses, 11.","DOI":"10.3390\/v11060562"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103663","DOI":"10.1016\/j.micpath.2019.103663","article-title":"Antigenic relationships between Caprine alphaherpesvirus 1 (CpHV-1) and Bovine alphaherpesvirus 1 (BoHV-1) and experimental CpHV-1 infection of kids and calves","volume":"136","author":"Martins","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/15384047.2018.1504722","article-title":"Caprine herpesvirus 1 (CpHV-1) as a potential candidate for oncolytic virotherapy","volume":"20","author":"Montagnaro","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_36","first-page":"655","article-title":"Herpesvirus infection in kids in Switzerland","volume":"121","author":"Mettler","year":"1979","journal-title":"Schweiz. Arch. Tierheilkd."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vetimm.2004.10.003","article-title":"Caprine herpesvirus-1 (CapHV-1) induces apoptosis in goat peripheral blood mononuclear cells","volume":"103","author":"Pagnini","year":"2005","journal-title":"Veter.-Immunol. Immunopathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jgm.1486","article-title":"Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus","volume":"12","author":"Kubo","year":"2010","journal-title":"J. Gene Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-09529-y","article-title":"The ERK-1 function is required for HSV-1-mediated G1\/S progression in HEP-2 cells and contributes to virus growth","volume":"7","author":"Colao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1128\/JVI.73.10.8245-8255.1999","article-title":"Perturbation of Cell Cycle Progression and Cellular Gene Expression as a Function of Herpes Simplex Virus ICP0","volume":"73","author":"Hobbs","year":"1999","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fcimb.2018.00396","article-title":"Breaking Bad: How Viruses Subvert the Cell Cycle","volume":"8","author":"Fan","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_43","first-page":"652","article-title":"Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma","volume":"13","author":"Forte","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"ref_45","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"Clarke","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Suavet, F., Champion, J.-L., Bartolini, L., Bernou, M., Alzieu, J.-P., Brugidou, R., Darnatigues, S., Reynaud, G., Perrin, C., and Adam, G. (2016). First Description of Infection of Caprine Herpesvirus 1 (CpHV-1) in Goats in Mainland France. Pathogens, 5.","DOI":"10.3390\/pathogens5010017"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: Biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0092-8674(00)81678-5","article-title":"CD46 Is a Cellular Receptor for Human Herpesvirus 6","volume":"99","author":"Santoro","year":"1999","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"25964","DOI":"10.1074\/jbc.M302373200","article-title":"Interaction of Glycoprotein H of Human Herpesvirus 6 with the Cellular Receptor CD46","volume":"278","author":"Santoro","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1099\/0022-1317-79-8-1983","article-title":"Bovine herpesvirus type 1 glycoprotein H is essential for penetration and propagation in cell culture","volume":"79","author":"Meyer","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cgt.7700548","article-title":"The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider","volume":"9","author":"Vile","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2009.088","article-title":"Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-\u03b2 for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy","volume":"21","author":"Saloura","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_55","first-page":"133","article-title":"Oncolytic virotherapy for human malignant mesothelioma: Recent advances","volume":"4","author":"Boisgerault","year":"2015","journal-title":"Oncolytic Virotherapy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","article-title":"Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma","volume":"5","author":"Adusumilli","year":"2006","journal-title":"Cancer Biol. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/12\/2458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:59Z","timestamp":1760168579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/12\/2458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":56,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["v13122458"],"URL":"https:\/\/doi.org\/10.3390\/v13122458","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]}}}